Changes in NAWM and NAGM are crucial in MS progression, challenging the traditional lesion-centric model. Subtle alterations in myelin integrity, immune cell function, and neuronal connectivity ...
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...
Researchers discover that the nerve cells that make us uniquely human are also uniquely vulnerable to dying during the waves ...
Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...
A hidden mechanism in MS may be damaging neurons at their genetic core, offering a potential new way to slow the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results